Clinical TrialID 5542

Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis

NCT04173429

Liver Cirrhosis|Portal Vein Thrombosis

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
5542
Evidence Id
5542
Core Evidence Id
5542
Source Clinical Trial Id
5524
Herb2 Clinical Trial Id
HBCT005524
Nct Id
NCT04173429
Title
Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis
Status
Completed
Phase
Phase 4
Study Result
Yes
Study Condition
Liver Cirrhosis|Portal Vein Thrombosis
Study Type
Interventional
Study Design
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Intervention
DRUG: Nadroparin calcium, warfarin
Intervention Allocation
Randomized
Intervention Model
Parallel
Intervention Mask
Single
Intervention Purpose
Treatment
Gender
All
Age
Adult, Older_Adult
Enrollment
64
Outcome Measure
Recanalization Rate, For each venous segment, the vein and residual patent lumen were outlined at the level of the maximum thrombosis. Total lumen area and patent lumen area were calculated with commercially available software. The degree of thrombus occlusion was estimated as a percentage by thrombosis area/total lumen area×100%. The primary outcome was the overall recanalization rate, both complete and partial. Complete recanalization was referred to the complete disappearance of the thrombus in the portal vein trunk, at least one of the two intrahepatic portal vein branches, SMV and SV. Partial recanalization was defined as a more than 50% reduction of the thrombus, with the thrombus not extending to other veins., 6 months
Sponsor Collaborator
Qilu Hospital of Shandong University
Funded By
OTHER
Location
Department of Gastroenterology,Qilu Hospital,Shandong University, Jinan, Shandong, 250012, China
Other Id
2019126-QILU
Start Date
2017-01-01
Primary Completion Date
2020-01-31
Completion Date
2020-01-31
First Posted
2019-11-22
Results First Posted
2021-03-02
Last Update Posted
2021-03-02
Study Document
Study Protocol, https://cdn.clinicaltrials.gov/large-docs/29/NCT04173429/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/29/NCT04173429/SAP_001.pdf
Study Url
https://clinicaltrials.gov/study/NCT04173429
Title Cn
Title En
Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis
Bilingual Status
semi_complete